Human rabies virus immune globulin

Identification

Name
Human rabies virus immune globulin
Accession Number
DB11603
Type
Biotech
Groups
Approved
Biologic Classification
Protein Based Therapies
Polyclonal antibody (pAb)
Description

IMOGAM Rabies Pasteurized is indicated for post-exposure prophylaxis in persons suspected of exposure to rabies, who have not previously received a complete immunization regimen with a cell culture produced rabies vaccine.

Persons previously vaccinated with other types of rabies vaccines in whom adequate antibody levels have not been demonstrated should receive full post-exposure prophylaxis with RIG and a cell culture-produced rabies vaccine.

IMOGAM Rabies Pasteurized should be administered promptly after exposure, in conjunction with rabies vaccine. If IMOGAM Rabies Pasteurized is not administered as recommended at the initiation of the post-exposure rabies vaccine series, it can be administered up to eight days following the first dose of the rabies vaccine. Since rabies vaccine-induced antibody begins to appear within one week, there is no value in administering rabies immune globulin more than eight days after rabies vaccination has begun.

Recommendations for passive and/or active immunization after exposure to an animal suspected of having rabies have been outlined by the National Advisory Committee on Immunization (NACI), the Advisory Committee on Immunization Practices (ACIP), and the World Health Organization (WHO).

Protein chemical formula
Not Available
Protein average weight
Not Available
Sequences
Not Available
Synonyms
  • Rabies immune globulin
  • Rabies immune globulin (human)
  • Rabies immune globulin human
  • Rabies immune globulin, human
  • Rabies immune globulin,human
  • Rabies immunoglobulins
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Hyperab Rabies Immune Globulin HumanLiquid16.5 %IntramuscularCutter Med & Biol, Division Of Miles Canada Ltd.1985-12-311998-09-25Canada
HyperRABInjection, solution300 [iU]/1mLInfiltration; IntramuscularGrifols1974-06-12Not applicableUs
Hyperrab S/dSolution150 unitIntramuscularGrifols Therapeutics Inc.1997-10-09Not applicableCanada
Hyperrab S/dInjection150 [iU]/1mLIntramuscularGrifols1996-08-14Not applicableUs
Imogam Rabies Inj 150unit/mlLiquid150 unitIntramuscularPasteur mÉrieux Serums Et Vaccins, s.a.1991-12-311999-08-12Canada
Imogam Rabies PasteurizedSolution150 unitIntramuscularSanofi Pasteur Limited1999-04-30Not applicableCanada
Imogam Rabies-HTInjection, solution150 [iU]/1mLIntramuscularSanofi Pasteur Limited1984-04-27Not applicableUs
KedrabInjection, solution150 [iU]/1mLIntramuscularKedrion Biopharma Inc.2017-11-08Not applicableUs
RabAvertPowder, for solution2.5 unitIntramuscularGlaxosmithkline Inc2005-05-16Not applicableCanada
Categories
UNII
95F619ATQ2
CAS number
Not Available

Pharmacology

Indication

For use in prophylaxis against rabies virus in patients who have been exposed to the virus and are immunocompromised or have not previously recieved the rabies vaccine [Label].

Associated Therapies
Pharmacodynamics

Rabies immune globulin prevents viral invasion of the central nervous system.

Mechanism of action

Rabies immune globulin binds the rabies virus, preventing it from invading the central nervous system [Label]. This affords time for the rabies vaccine, which is also administered in cases of rabies exposure, to induce an immune response to destroy the virus. Rabies immunoglobulin should only be administered up to eight days after exposure as the host begins to produce sufficient antibodies to the virus one week after exposure. Repeat dosing should also be avoided as it may interfere with induction of immune response by the rabies vaccine.

TargetActionsOrganism
ARabies lyssavirus
antibody
Rabies lyssavirus
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity

No toxicological studies have been performed. Isolated cases of angioneurotic edema, skin rash, nephrotic syndrome, and anaphylactic shock after injection have been noted [Label].

Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with Human rabies virus immune globulin.
19-norandrostenedioneThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Human rabies virus immune globulin.
2-MethoxyethanolThe risk or severity of adverse effects can be increased when 2-Methoxyethanol is combined with Human rabies virus immune globulin.
5-androstenedioneThe risk or severity of adverse effects can be increased when 5-androstenedione is combined with Human rabies virus immune globulin.
AbataceptThe risk or severity of adverse effects can be increased when Abatacept is combined with Human rabies virus immune globulin.
AbetimusThe risk or severity of adverse effects can be increased when Abetimus is combined with Human rabies virus immune globulin.
AbituzumabThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Abituzumab.
ActeosideThe risk or severity of adverse effects can be increased when Acteoside is combined with Human rabies virus immune globulin.
AdalimumabThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Adalimumab.
AdecatumumabThe therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Adecatumumab.
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Substance
347911213
AHFS Codes
  • 80:04.00 — Serums
  • 80:12.00 — Vaccines

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedTreatmentRabies1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
LiquidIntramuscular16.5 %
Injection, solutionInfiltration; Intramuscular300 [iU]/1mL
InjectionIntramuscular150 [iU]/1mL
SolutionIntramuscular150 unit
LiquidIntramuscular150 unit
Injection, solutionIntramuscular150 [iU]/1mL
Powder, for solutionIntramuscular2.5 unit
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available

Taxonomy

Description
Not Available
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
Not Available
Substituents
Not Available
Molecular Framework
Not Available
External Descriptors
Not Available

Targets

1. Rabies lyssavirus
Kind
Organism
Organism
Rabies lyssavirus
Pharmacological action
Yes
Actions
Antibody

Drug created on June 01, 2016 14:49 / Updated on October 16, 2018 08:43